As the Penn Medicine Co-Investment Program Director, Carter leads Penn Medicine’s investments in the cell therapy, gene therapy, mRNA, lipid nanoparticle, and connected health sectors. Utilizing multiple decades of experience as both an entrepreneur and an investor, he sources Penn Medicine faculty-driven investment opportunities, manages relationships with co-investors, completes due diligence, and supports the governance of the program companies.
He was previously a Managing Director with Cross Atlantic Capital Partners, a venture capital firm with 4 funds and over $500 million under management and founded and managed two software companies, Quazant Technology and Acorn Systems, which was acquired by Ignite Technologies in July 2014.
Carter holds an MBA from Columbia University and a BA in Philosophy, Politics and Economics from the University of Pennsylvania.